175 related articles for article (PubMed ID: 12138495)
1. Clinical potential of proteomics in the diagnosis of ovarian cancer.
Ardekani AM; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2002 Jul; 2(4):312-20. PubMed ID: 12138495
[TBL] [Abstract][Full Text] [Related]
2. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
4. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
5. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
6. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer.
Yu JK; Zheng S; Tang Y; Li L
J Zhejiang Univ Sci B; 2005 Apr; 6(4):227-31. PubMed ID: 15754417
[TBL] [Abstract][Full Text] [Related]
7. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
8. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
9. Use of proteomic patterns in serum to identify ovarian cancer.
Petricoin EF; Ardekani AM; Hitt BA; Levine PJ; Fusaro VA; Steinberg SM; Mills GB; Simone C; Fishman DA; Kohn EC; Liotta LA
Lancet; 2002 Feb; 359(9306):572-7. PubMed ID: 11867112
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
11. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
12. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
13. Advances in the early detection of ovarian carcinoma.
Garner EI
J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
[TBL] [Abstract][Full Text] [Related]
14. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS; Bast RC
Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
[TBL] [Abstract][Full Text] [Related]
16. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
Bast RC
Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
18. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Høgdall C; Fung ET; Christensen IJ; Nedergaard L; Engelholm SA; Petri AL; Risum S; Lundvall L; Yip C; Pedersen AT; Hartwell D; Lomas L; Høgdall EV
Gynecol Oncol; 2011 Nov; 123(2):308-13. PubMed ID: 21855971
[TBL] [Abstract][Full Text] [Related]
19. [Study for drug-resistance of epithelial ovarian cancer by serum protein profiling].
Zhang WY; Zhu LR; Zheng YH; Zhou L; Zhang JZ; Wu JH; Liao QP
Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1326-9. PubMed ID: 19615186
[TBL] [Abstract][Full Text] [Related]
20. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
